RxDoctor Payments Data

Troy Thielen, PA

Physician Assistant · Okemos, MINPI 1720445810

Payments from drug & device makers

$5,848in general payments, 2019–2025

Across 343 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$983
  • Amgen$885
  • AbbVie$494
  • Otsuka America Pharmaceutical, Inc.$483
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$468
  • AstraZeneca$393
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,848100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,848 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$1,690
Medicare patients
15
Services billed
152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$44,822
TrulicityDulaglutide29$37,602
OzempicSemaglutide26$33,458
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$28,126
JardianceEmpagliflozin13$16,107
MyrbetriqMirabegron11$14,076
MounjaroTirzepatide12$12,265
Spiriva RespimatTiotropium Bromide11$5,726
Atorvastatin Calcium167$2,695
Albuterol Sulfate HfaAlbuterol Sulfate54$2,620
Levothyroxine Sodium145$1,711
Rosuvastatin Calcium67$1,580
Duloxetine Hcl52$1,534
Tamsulosin Hcl70$1,488
Omeprazole104$1,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$365$49,86741 claims
PfizerEliquis$139$44,82251 claims
Novo NordiskOzempic$983$33,45826 claims
GSKTrelegy Ellipta$275$28,12634 claims
Boehringer IngelheimJardiance, Spiriva Respimat$59$21,83324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Okemos

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →